Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I，Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LB4330 in Patients With Advanced Solid Tumors（MEETCD8-001）

NCT05707676 is registered in ClinicalTrials.gov with L & L Bio Co., Ltd., Ningbo, China as lead sponsor.

NCT NCT05707676
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05707676 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I，Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LB4330 in Patients With Advanced Solid Tumors（MEETCD8-001）
Lead sponsor
L & L Bio Co., Ltd., Ningbo, China
Phase
Phase 1
Overall status
Terminated
Start date
November 30, 2022
Completion date
December 20, 2024
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor